Publications, Pharmaceutical

Using Raman for the characterization of nasal drug suspension products

Demonstrating bioequivalence (BE) in locally acting nasal suspension drug products is a significant challenge, though essential for the commercialization of generics.

This paper presents studies of the utility of morphologically directed Raman spectroscopy (MDRS) within this context, based on measurement of the particle size distribution of mometasone furoate monohydrate (MFM) in different suspension formulations. FDA product specific guidances for nasal drug suspension products highlight the potential to use MDRS in place of comparative clinical endpoint studies, a strategy with potential to accelerate generics to market. Drug substance particle size distribution data were measured using MDRS for a reference listed drug (Nasonex) and four test formulations. Other characteristics such as dissolution profile were also assessed. The data highlight the potential of dissolution testing as an orthogonal, critical analytical tool in BE studies.

Download Publication
28 Apr 2021

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

25 May 2023

Exploring the Benefits and Future Possibilities of Nasal Drug Delivery and Drug Repos...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
11 May 2023

Why Pharma should care about circular packaging – Futurity leading the way

Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Sustainability, Device Innovations

Read More
10 May 2023

Navigating the Development for Orally Inhaled and Nasal Drug Products

Publications, Pharmaceutical, Product Solutions, Device Innovations, Market Insights

Read More
2 May 2023

Using Intranasal Delivery for Drug Repositioning: A Compelling Proposition for Lifecy...

Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
1 2 3 20
Back To Top